Ionis will present detailed data from its Phase 3 CORE and CORE2 studies of olezarsen (brand name Tryngolza) for severe hypertriglyceridemia at the American Heart Association Scientific Sessions in New Orleans. The late‑breaking session is scheduled for Saturday, November 8, 2025, from 9:40 – 9:50 a.m. ET.
Ionis will also host a webcast at 3:00 p.m. ET on the same day, allowing stakeholders to review the results. The topline data from the CORE and CORE2 studies already showed a highly statistically significant reduction in fasting triglycerides and a decrease in acute pancreatitis events, with a favorable safety profile.
Olezarsen, marketed as Tryngolza, is an antisense oligonucleotide that targets apolipoprotein C‑III to lower triglyceride levels. It was the first FDA‑approved treatment for familial chylomicronemia syndrome (FCS) on December 19, 2024, and received EU approval on September 19, 2025. Ionis plans to submit a supplemental new drug application to the FDA by the end of 2025, aiming to expand the drug’s indication to severe hypertriglyceridemia.
The presentation of detailed data is a key milestone in the drug’s development and regulatory strategy, potentially accelerating FDA approval and commercialization for a broader patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.